
research
STRIDE study: GLP1s vs peripheral artery disease (PAD)
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
research
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:news
Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
company:novo-nordisk
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:news
Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
category:news
We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.
company:hims
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
chemical:semaglutide
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
country:mexico
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:watercooler
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.
category:watercooler
We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.